Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Guangdong Fapon Biotech Co., Ltd.

Download Mobile App





RainSure Exhibits Hematology and Cell Analysis Technologies at MEDICA 2026

By LabMedica International staff writers
Posted on 17 Nov 2026

RainSure Scientific (San Jose, CA, USA) is showcasing its molecular diagnostics and life sciences technologies at MEDICA 2026, taking place November 16–19 in Düsseldorf, Germany. More...

At Hall 3, Stand B20, the company is highlighting its hematology testing solutions, OMNIS Flow full-spectrum flow cytometer, OmniPlex dPx multi-omics platform, and UriFind urine-based cancer detection assay. These technologies support applications ranging from molecular disease monitoring and cellular analysis to cancer detection and cell and gene therapy research.

Among the featured solutions is RainSure's hematology portfolio, which combines KindStar's targeted next-generation sequencing (NGS) panels with digital PCR (dPCR) technology. The portfolio covers six disease categories, including myeloid leukemia, chronic lymphocytic leukemia (CLL), acute lymphoblastic leukemia (ALL), lymphoma, and plasma cell dyscrasias. A key component is the FDA 510(k)-cleared FastPlex BCR-ABL (p210) %IS digital PCR Kit, designed for molecular monitoring of treatment response in patients with previously diagnosed Philadelphia chromosome-positive chronic myeloid leukemia.

RainSure is also presenting the OMNIS Flow full-spectrum flow cytometer, equipped with five lasers and supporting 79 colors for high-parameter cellular analysis. The system enables detailed characterization of cell populations for research applications. Another featured technology is the OmniPlex dPx platform, which simultaneously detects proteins and nucleic acids to support characterization of adeno-associated viruses (AAVs), lipid nanoparticles (LNPs), and extracellular vesicles (EVs) in cell and gene therapy research and development.

The company is also highlighting UriFind, developed by AnchorDx, a non-invasive urine-based DNA methylation test intended for the early detection and auxiliary diagnosis of urothelial carcinomas, including cancers of the bladder, renal pelvis, and ureter. The assay identifies ONECUT2 and VIM epigenetic biomarkers using a random urine sample of approximately 100 mL. According to RainSure, UriFind has received FDA Breakthrough Device designation, which facilitates regulatory development and review but does not constitute marketing authorization. Together, these technologies reflect RainSure's focus on precision diagnostics and life sciences research.


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Automated Clinical Chemistry Analyzer
Envoy 500+
Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Researchers combined a blood-based biomarker of Alzheimer’s disease with age, sex, and genetic risk to estimate future cognitive impairment risk in asymptomatic adults (Image Credit: Adobe Stock)

Blood Biomarker Model May Help Estimate Five- and 10-Year Cognitive Impairment Risk

Estimating future cognitive impairment risk remains challenging in cognitively healthy adults, particularly when biomarker findings are reduced to simple positive or negative results. Because mild cognitive... Read more

Molecular Diagnostics

view channel
Image: A new study links broad genomic sequencing before first-line therapy to longer survival, supporting its role in treatment decisions (Image Credit: Shutterstock)

Study Supports Broad Genomic Profiling Before First-Line Lung Cancer Treatment

Biomarker testing plays a critical role in advanced non-small cell lung cancer by identifying patients who may benefit from targeted therapies. However, testing only one or two genes can miss actionable... Read more

Immunology

view channel
Image: The findings underscore the importance of aligning allergy testing with clinical history and diagnostic guidelines to reduce inappropriate testing and its consequences (Image Credit: iStock)

Survey Finds Gap Between Food Allergy Testing Awareness and Clinical Practice

Food allergy evaluation can be challenging when laboratory results do not match clinical symptoms. Broad food allergy panels may detect sensitization without confirming an actual allergy, potentially leading... Read more

Microbiology

view channel
Image: Malaria is caused by Plasmodium parasites, primarily transmitted through the bites of infected female Anopheles mosquitoes (Image Credit: Adobe Stock)

Complete Malaria Genomes Could Improve Species Identification and Surveillance

Malaria remains a major global health challenge, with an estimated 282 million cases and 610,000 deaths worldwide in 2024. Although most research has focused on Plasmodium falciparum, Plasmodium ovale... Read more

Industry

view channel
Image Credit: iStock

C2N Makes PrecivityAD2 Alzheimer’s Blood Test Available to Clinicians

Diagnosing Alzheimer’s disease can be challenging, particularly in patients with mild cognitive impairment or early dementia. Assessing brain amyloid pathology can guide clinical decisions, but diagnostic... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.